SpliceBio Raises €130M Series B to Advance Stargardt Gene Therapy and Expand Genetic Medicines
SpliceBio has raised €130M in Series B funding to advance its gene therapy for Stargardt disease and expand its pipeline using a proprietary protein splicing platform.
Barcelona-based biotech SpliceBio has secured €130 million in Series B financing to accelerate the development of its lead gene therapy candidate for Stargardt disease and expand its pipeline of genetic medicines. The raise marks a major milestone for the company’s proprietary protein splicing platform, which is designed to overcome key limitations in gene delivery.
The round was co-led by Forbion and UCB Ventures, with participation from a strong syndicate of new and existing investors including Andera Partners, EQT Life Sciences, Invivo Capital, Ysios Capital, Kurma Partners, and the European Innovation Council (EIC) Fund.
The funding will primarily support the advancement of SB-007, SpliceBio’s lead program targeting Stargardt disease, a debilitating inherited retinal disorder caused by mutations in the ABCA4 gene. Because of the gene’s large size, it has long been out of reach for conventional AAV-based gene therapies. SpliceBio’s technology provides a way to address this challenge and meet a significant unmet medical need.
“Our protein splicing platform opens the door to treating diseases that have been out of reach for traditional gene therapy,” said Miquel Vila-Perelló, CEO and co-founder of SpliceBio. “With this financing, we’re taking a significant step toward bringing SB-007 into the clinic and expanding our pipeline into other indications where large genes have been a limiting factor.”
SpliceBio’s proprietary Protein Splicing technology allows for the reassembly of large functional proteins from smaller gene fragments delivered via standard AAV vectors. This approach could significantly expand the range of diseases that gene therapy can effectively address, particularly those involving mutations in oversized genes that cannot be packaged into a single vector.
In addition to advancing SB-007 into clinical development, the Series B funding will support internal manufacturing capabilities and accelerate the company’s discovery programs in both ocular and systemic genetic diseases.
As gene therapy continues to evolve, safe and efficient delivery remains one of the field’s biggest challenges. With its innovative platform and strong investor backing, SpliceBio is positioning itself as a leader in the next generation of genetic medicines, aiming to deliver transformative therapies where existing approaches have yet to succeed.
Author
BioFocus Newsroom